期刊文献+

西格列汀上市后致皮肤不良反应的分析

原文传递
导出
摘要 目的:对西格列汀上市以来所引起的皮肤不良反应进行统计分析。方法:回顾性分析西格列汀2010年1月-2014年6月不良事件报告系统(AERS)统计的ADR报告数据。结果:皮肤不良反应患者共计520例;发病年龄主要集中在45-65岁及65岁以上患者;用药时间在1-24个月者较多;用药剂量达50-100 mg/天时易出现皮肤不良反应症状。结论:通过对西格列汀皮肤不良反应进行挖掘评价,进一步了解了西格列汀所引起的不良症状。
作者 米婷婷
机构地区 南阳市中心医院
出处 《按摩与康复医学》 2015年第4期77-78,共2页 Chinese Manipulation and Rehabilitation Medicine
  • 相关文献

参考文献2

二级参考文献30

  • 1Jadad AR,Moore RA,Carroll D. Assessing the quality of reports of randomized clinical trials:is blinding necessary[J].{H}Controlled Clinical Trials,1996,(01):1-12.
  • 2Aschner P,Kipnes MS,Lunceford JK. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes[J].{H}DIABETES CARE,2006,(12):2632-2637.
  • 3Barzilai N,Guo H,Mahoney EM. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes:a randomized,double-blind,placebo-controlled trial[J].{H}CURRENT MEDICAL RESEARCH AND OPINION,2011,(05):1049-1058.
  • 4Charbonnel B,Karasik A,Liu J. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone[J].{H}DIABETES CARE,2006,(12):2638-2643.
  • 5Goldstein BJ,Feinglos MN,Lunceford JK. Effect of initial combination therapy with sitagliptin,a dipeptidyl peptidase-4 inhibitor,and metformin on glycemic control in patients with type 2 diabetes[J].{H}DIABETES CARE,2007,(08):1979-1987.
  • 6Hanefeld M,Herman GA,Wu M. Once-daily sitagliptin,a dipeptidyl peptidase-4 inhibitor,for the treatment of patients with type 2 diabetes[J].{H}CURRENT MEDICAL RESEARCH AND OPINION,2007,(06):1329-1339.
  • 7Hermansen K,Kipnes M,Luo E. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor,sitagliptin,in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin[J].{H}Diabetes Obesity & Metabolism,2007,(05):733-745.
  • 8Mohan V,Yang W,Son HY. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China,India,and Korea[J].{H}Diabetes Research and Clinical Practice,2009,(01):106-116.
  • 9Nonaka K,Kakikawa T,Sato A. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes[J].{H}Diabetes Research and Clinical Practice,2008,(02):291-298.
  • 10Raz I,Hanefeld M,Xu L. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus[J].{H}DIABETOLOGIA,2006,(11):2564-2571.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部